Skip to main content
. 2014 Apr 18;16(3):378–386. doi: 10.4103/1008-682X.122876

Table 1.

Active trials with PI3K pathway inhibitors in prostate cancer and solid tumor malignancies

graphic file with name AJA-16-378-g002.jpg